Takeda makes US R&D appointment
This article was originally published in Scrip
Dr Azmi Nabulsi has been appointed president of the Takeda Global Research & Development Center in the US. He succeeds Dr Nancy Joseph-Ridge, who has been named general manager of the Japanese firm's US pharmaceutical development division. This operates under Takeda Pharmaceuticals International, a new wholly owned US entity formed in a recent restructuring of corporate R&D activities (scripnews.com, March 31st, 2009). Dr Nabulsi joined Takeda in 2004 and was most recently general manager of the strategic development department at its Osaka headquarters.
You may also be interested in...
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.